Investment Q&A

Q: Good Afternoon
I am attempting to diversify away from NVDA due to its large percentage of my holdings. I also have good gains in both NBIS and VRT although I am comfortable with their current weighting and both have room to grow. Assuming all 3 will somewhat move in unison does it make more sense to pick a non AI related stock rather than add to NBIS and VRT? If that is the case can you give me suggestions on what to add?
Thank you

Q: Could you comment on CRWV. I can’t find comments post earnings. The financial results disappointed or the stock was ahead of itself. Any views long term on buying? Entry point or wait for momentum?

Q: I already have a little of NBIS. I am wondering if I should get into a CRWV position now that the price has dipped.

Otherwise, I would to my small NBIS position (80 shares @ USD 40).

At what price would you start a half position in CRWV? At what price would add to an existing NBIS position.

Q: Kraken reports on Thursday. What are the expectations? What one aspect if positive would really boost the share price and what metric if highly negative would cause price damage? What might one worry about (surprise) in the results.

Q: This may, (or may not) be a stupid, amateur question:
Some BIP.UN metrics are good, but the PB is 14.97 and PE !,011.45!
How can one buy something like that?
This is an extreme case, but you now frequently recommend stocks at 40, 50 and higher PE's. Leaving all else aside, that, at minimum, is a sign of a stock priced to perfection, no?
Thanks for your comment.
Jerry

Q: If you combine 2 factors : dividends + dividend growth, on a 5 year's timespan, would you favor BN or BAM ?

Q: I have held MX for a few years and watched it bounce up and down and have never been smart enough to take advantage of its cyclicality and sell on its way up. Its currently at the lower end of its trading band. If it were you, would you wait for the next leg up to sell and move into CNQ or would you make the trade now? My hesitancy is that MX would appear to have a much higher short/medium term potential than CNQ and I would hate to miss that,

Thanks
Scott

Q: I would appreciate your comments on the firing of the CEO and the board (finally?) getting involved to hopefully kickstart the company. In these situations it is usually best to hold and see what happens?

Appreciate your insight.

Paul F.

Q: Please an update after their last quarter numbers.
Thx

Q: Peter; With Canadian rates low, and may go lower, would it not be to BPY’s advantage to redeem this proffered at $25.00 next July? Any other comments would be appreciated. Thanks.
Rod

Q: I hold HHL in my RRIF which is primarily focused on income. I am considering switching HHL to
HHLE. This would increase my income by approximately 30% on this money and allow me to keep the same list of healthcare stocks. Does this make sense; any downsides ; am I missing anything?

As an aside , I am at breakeven with HHL as the sector is under pressure from Trump and also United Healthcare has dampened the sector. But with Trump wanting lower drug prices , the companies will be going overseas to compensate for lower US revenue as witnessed by Eli Lilly raising international prices for Mounjaro.
Thanks .Derek

Q: PLEASE SUGGEST A COUPLE OF PASSIVE, EQUAL WAITED SP5000 FUNDS DENOMINATED IN US DOLARS. tHANKS

Q: In terms of positioning, the easiest answer is to just rebalance and trim some areas that have done well over the last few months and add to more defensive areas like fixed income or maybe more value oriented areas.

This is what 5i responded to an earlier question. In your view, what would those « more value oriented «  areas be?
Thanks as always

Q: Good morning,

Could you please briefly comment on SE's recent results? As well, could you rank the potential buy order of these seven growth stocks today? Thanks,

Brad

Q: Please comment on their earnings and outlook going forward. Please rate as a buy, hold or sell.

Q: I hold these 3 stocks for income and have seen capital erosion in recent years with weakness in the telecom sector. In terms of industry concentration, how much overlap is there between the three (Telus has held up best), would you recommend letting one or two of them go, which one(s), and what would you recommend in the general sector as a replacement (US or Cdn)?

In particular, I am curious about BCE's prospects following the US acquisition after selling MLSE stake, dividend cut, debt, and scaling back of capex.

Q: Hello team
with the Fed govt going into more debt , interest rate pending cut by Bank of Canada
what is going to happen to the bond funds in gneral? I do have XBB, XLB all losing some grounds
If indeed there is inflation due to the tariffs hitting the basic goods and little growth, how does it affect the bond funds?
thank you
Michael

Q: Most of my investing style is focused on Canadian high quality compounders and the US market using ETFs. I have really tried to drill in my head that drawdowns of 20-30% happen quite frequently to quality compounders for no significant reason other than they can randomly occur. I try my best to ignore them and focus on the long term future. My biggest holdings are CSU, TOI, and LMN. Instead of focusing on the current drawdown, where do you see these companies in a 5-10 year time horizon? Will CSU be able to acquire as many companies? Will it compound as quickly as it has before. Do you feel that TOI and LMN will be that faster growers in the future compared to CSU. What is the possibility of future spin outs for CSU? So far the 2 spin outs have worked well and followed CSU’s acquisition and incentive playbook.

Q: I have $500,000 from sale of house that I need to park until January when I can contribute it back to my TFSA. Given the recent strong markets and the fact we are going I to seasonally weak months I don’t want to be exposed to market risk. Once back in my TFSA I will put the money to work in the markets.
I was thinking of using HSAV as the returns are by way of unit price appreciation which would be taxed more favourably than interest paid out in CASH or PSA. The unit price growth in HSAV is somewhat erratic which is a bit concerning.
Your thoughts or other suggestions.

Q: Please provide your view on the latest quarterly report and outlook.
Thanks